MedTrace Logo

A Comparative Study of KSO-0400 in BPH Patients With LUTS

NCT01222650 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2011-07-04

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of KSO-0400 compared to placebo for the treatment of LUTS caused by BPH.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

DRUG

KSO-0400

DRUG

KSO-0400

DRUG

Silodosin

DRUG

Placebo

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Katsumi Hontani · Clinical Development Dept.,Kissei Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222650 on ClinicalTrials.gov